This week in therapeutics




Licensing status

Publication and contact information

Cardiovascular disease

Myocardial infarction (MI)

CD20; chemokine CC motif ligand 7 (CCL7; MCP3; SCYA6)

Human serum and mouse studies suggest antibodies against CD20 could help treat MI. In mouse models of MI, B cells and monocytes in cardiac tissue and levels of Ccl7 secreted by B cells in blood and cardiac tissue were higher than those in healthy controls. In these models, an anti-Cd20 mAb decreased Ccl7 levels and infarct size and increased cardiac function compared with vehicle. In serum from patients with MI, CCL7 levels were associated with risk of death and recurrent MI. Planned work includes testing anti-CD20 antibodies in patients following MI.
Rituxan/MabThera rituximab, an antibody against CD20 from Biogen Idec Inc. and the Genentech Inc. unit of Roche, is marketed for a variety of autoimmune diseases and hematological cancers.
Arzerra ofatumumab, a mAb against CD20 from Genmab A/S and GlaxoSmithKline plc, is marketed for chronic lymphocytic leukemia (CLL; see Anti-CD20 therapy for heart attack, page 1).

SciBX 6(37); doi:10.1038/scibx.2013.1029
Published online Sept. 26, 2013

Patent application filed by the Institut National de la Santé et de la Recherche Médicale (INSERM) and University of Cambridge; available for licensing

Zouggari, Y. et al. Nat. Med.; published online Sept. 15, 2013;
Contact: Ziad Mallat, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France